To investigate the effect of GAS2 silencing on primary T‐ALL cells, validated shGAS2 from a previous report was delivered into these cells [13], and the effect of GAS2 silencing on normal CD3+ cells was evaluated as a control. Here, GAS2 is linked to acute lymphoblastic leukemia.